Roche reins in the TIGIT expectations
Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Merck’s big ADC deal takes a blow
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
Investors don't buy Lyell's solid tumour Car-T success
The ROR1 data are sketchy, and lung toxicity clouds prospects.
Toxicity hits BioNTech’s MediLink tie-up
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
Bayer changes tack in targeted lung cancer
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
We haven't lost focus, BioNTech insists
The company defends its cancer strategy, and says it's not a me-too developer.
